Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis
Abata Therapeutics Appoints Ellen Cahir-McFarland, Ph.D., as Chief Scientific Officer
Abata Therapeutics to Participate in Guggenheim’s 4th Annual Immunology and Neurology Day
Abata Therapeutics to Present at Upcoming September Investor Conferences
Abata Therapeutics to Participate in the Guggenheim I&I Spotlight Series – Treg-Based Therapies
Abata Therapeutics to Present at Upcoming Investor Conferences
Abata Therapeutics Appoints Sandy Lazzari as Chief People Officer
